Patent: 9,551,033
✉ Email this page to a colleague
Summary for Patent: 9,551,033
Title: | Gene expression markers of tumor resistance to HER2 inhibitor treatment |
Abstract: | The present invention concerns markers of resistance of HER2 expressing tumors to treatment with HER2 inhibitors, such as HER2 antibodies, including trastuzumab. |
Inventor(s): | Lee-Hoeflich; Si Tuen (Millbrae, CA), Stern; Howard (San Carlos, CA) |
Assignee: | Genentech, Inc. (South San Francisco, CA) |
Application Number: | 12/806,419 |
Patent Claims: | see list of patent claims |
Details for Patent 9,551,033
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | ⤷ Try a Trial | 2027-06-08 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 02/10/2017 | ⤷ Try a Trial | 2027-06-08 |
Genentech, Inc. | HERCEPTIN HYLECTA | trastuzumab and hyaluronidase-oysk | Injection | 761106 | 02/28/2019 | ⤷ Try a Trial | 2027-06-08 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |